SweetValueLab
Write for us

Henry Schein, Inc. — Wall Street Analyst Estimates & Price Targets

HSIC
NASDAQHealthcareMedical - DistributionCIK 0001000228henryschein.comAbout HSIC
Last close · Oct 16, 202686.38−0.61 (−0.70%)
Market cap$9.6B

6 firms' latest targets, last 90 days: median $97.50 ($92.00–$110.00), 13% above the last close.

Price and published targets

daily close, 12 months · each dot a target, a firm's latest darker
$60.0$80.0$100NovJan 2026MarMayJulSep2025-11-05 · Evercore ISI: $90.02025-11-05 · Barrington: $79.02025-12-08 · Barclays: $86.02026-01-20 · Mizuho Securities: $81.02026-02-23 · Baird: $1002026-02-24 · Leerink Partners: $87.02026-02-25 · Barrington: $97.02026-04-24 · Morgan Stanley: $64.02026-05-06 · UBS: $85.02026-05-06 · Mizuho Securities: $82.02026-05-06 · Baird: $97.02026-06-11 · BTIG: $1002026-07-08 · BMO Capital: $85.02026-07-28 · UBS: $89.02026-08-05 · Barrington: $1042026-08-05 · UBS: $94.02026-08-05 · Stifel: $95.02026-08-06 · Barclays: $1002026-08-19 · BTIG: $1102026-10-14 · Leerink Partners: $92.0
$60.0$80.0$100NovFebMayAug

Each firm's latest target

last 90 days · 6 firms
DateFirmTargetPreviousChangeVs price thenVs price now
2026-10-14Leerink Partners$92.00$87.00▲ 6%+8%+7%
2026-08-19BTIG$110.00$100.00▲ 10%+21%+27%
2026-08-06Barclays$100.00$86.00▲ 16%+12%+16%
2026-08-05Barrington$104.00$97.00▲ 7%+17%+20%
2026-08-05UBS$94.00$89.00▲ 6%+5%+9%
2026-08-05Stifel$95.00——+7%+10%

Consensus estimates

revenue and EPS by fiscal year · reported years marked
FYRevenueYoYEPSYoYRevenue rangeEPS rangeAnalysts
2022reported$12.6B+2%$3.91-12%est. $12.6B+0%est. $4.824
2023reported$12.3B-2%$3.16-19%est. $12.4B+0%est. $4.5310
2024reported$12.7B+3%$3.05-3%est. $12.8B-1%est. $4.759
2025reported$13.2B+4%$3.27+7%est. $13.1B+1%est. $4.9211
2026$13.9B+5%$5.39+10%$13.8B–$13.9B$5.35–$5.4312
2027$14.4B+4%$5.99+11%$14.3B–$14.6B$5.87–$6.2712
2028$15.0B+4%$6.60+10%$14.8B–$15.4B$6.00–$7.1812
2029$15.8B+5%$7.07+7%$15.7B–$16.0B$7.01–$7.196
A reported year shows the company's figures, with the consensus beside it (revenue against it in %). Reported EPS is GAAP diluted; the analysts' EPS usually leaves items such as stock compensation out, so the two are not like for like. Faded: a year the valuation models do not read — they read the first 3, and a later one only while 10 or more analysts cover every year up to it — or one under 5 analysts.

Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.